RALEIGH, N.C., April 30, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced the appointment of Gail F. Lieberman to its Board of Directors. The appointment was effective April 27, 2009, and fills a vacancy that had previously existed on the company's Board.
"I am pleased to be associated with a company that has significant growth prospects and offers so much hope through the products it develops," commented Ms. Lieberman.
Ms. Lieberman is the founder and Managing Partner of Rudder Capital, LLC, which provides financial and strategic advisory services for middle-market companies including M&A advisory and strategic consulting. She has been a Chief Financial Officer for Fortune 500 companies: Thomson Corporation's Financial & Professional Publishing division, Moody's Investor Service (D&B) and Scali, McCabe, Sloves (Ogilvy Group).
Ms. Lieberman has recently served as a Director for three public companies in the healthcare and aerospace sectors: I-Trax Inc. (Amex:DMX), Chair of Audit Committee, Member of Compensation and Strategy Committees, 2004-2008; TriPath Imaging Inc. (Nasdaq:TPTH), Member of Audit and Governance Committees, 2005-2006; Breeze-Eastern Corporation (Amex:BZC), Chair of Audit Committee, Member of Strategy Committee, 2005-2007.
Ms. Lieberman holds a BA in Mathematics and Physics and an MBA in Finance from Temple University.
About DARA BioSciences, Inc.
DARA is a Raleigh, North Carolina-based development-stage pharmaceutical company that acquires and develops promising drug candidates. DARA focuses its therapeutic development efforts on small molecules from late preclinical development through phase 2 clinical trials. DARA has a portfolio of drug candidates for neuropathic pain, type 2 diabetes, and psoriasis. For more information, please contact the Company at 919-872-5578 or visit our web site at www.darabio.com.
All statements in this news release that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934 as amended. Such forward-looking statements are subject to factors that could cause actual results to differ materially for DARA from those projected. Those factors include risks and uncertainties relating to DARA's ability to regain compliance with NASDAQ continued listing requirements, DARA's current cash position and its need to raise additional capital in the near term in order to be able to continue operations, DARA's ability to develop and bring new products to market as anticipated, the current regulatory environment in which the Company develops and sells its products, the market acceptance of those products, dependence on partners, successful performance under collaborative and other commercial agreements, competition, the strength of DARA's intellectual property, the intellectual property of others, and other risk factors identified in the documents DARA has filed, or will file, with the Securities and Exchange Commission. Copies of DARA's filings with the SEC may be obtained from the SEC Internet site at http://www.sec.gov. DARA expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DARA's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. DARA BioSciences and the DARA logo are trademarks of DARA BioSciences, Inc.